Implications of Drug-induced Phenotypical Resistance: Is Isoniazid Radicalizing ?

Overview

Journal Front Antibiot

Date 2025 Jan 16

PMID 39816411

Authors

Rjh Hammond

Frank Kloprogge

O Della Pasqua

Stephen H Gillespie

Affiliations

Soon will be listed here.

Abstract

Background: Tuberculosis treatment duration is long and does not guarantee eradication of infection. Shorter treatment regimens are a critical research objective to improve uptake and reduce the risk of relapse and bacterial resistance. The explanation for the need to continue treatment after patients are culture negative remains elusive. We have previously shown that the presence of lipid inclusions in mycobacterial cells is associated with an increase in antibiotic resistance.

Aim: We investigate the bactericidal effect of isoniazid and rifampicin on the expression of lipid inclusions and characterize the degree of the associated phenotypic antibiotic resistance to a range of anti-tuberculosis agents in current use.

Methods: Antibiotic killing effect for both and were investigated by both hollow fiber bioreactor (HFS) studies and static time kill curve (STKC) experiments. Following STKC cultures were stained with resazurin, Sytox green and Nile red to establish their live/dead (resazurin positive/Sytox positive) and lipid inclusion status, respectively. In addition, was studied in the hollow fiber bioreactor model (HFS) and exposed to isoniazid (H) and rifampicin (R). The MIC of current antituberculosis agents for cells from the treated hollow fiber experiments were tested.

Results: Antibiotic killing was similar for both species. For ; isoniazid was ineffective at the established MIC (1 mg/L) in the hollow fiber bioreactor but rifampicin reduced the viable count rapidly at MIC (0.4 mg/L). When the two drugs were combined at their respective MICs the killing effect was significant and greater than separately. Cells exposed to isoniazid (1x and 9x MIC) for 168 h showed considerable numbers of recoverable viable cells when compared with a combination of 1x MIC R & H where there were no viable cells detectable. For both drugs the number of lipid body positive cells increased over time and this effect was most pronounced for isoniazid and was associated with phenotypic resistance to multiple anti-tuberculosis drugs.

Conclusion: Our results showed that isoniazid is a potent stimulator of lipid body accumulation, culture persistence, and phenotypic resistance to multiple anti-tuberculosis drugs. These findings emphasize the importance of understanding mechanisms of drug-drug interactions and phenotypic resistance in regimen building.

References

Diacon A, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald P . 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012; 380(9846):986-93. DOI: 10.1016/S0140-6736(12)61080-0. View

Dorman S, Nahid P, Kurbatova E, Phillips P, Bryant K, Dooley K . Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021; 384(18):1705-1718. PMC: 8282329. DOI: 10.1056/NEJMoa2033400. View

Baron V, Chen M, Hammarstrom B, Hammond R, Glynne-Jones P, Gillespie S . Real-time monitoring of live mycobacteria with a microfluidic acoustic-Raman platform. Commun Biol. 2020; 3(1):236. PMC: 7224385. DOI: 10.1038/s42003-020-0915-3. View

Wayne L, Hayes L . An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996; 64(6):2062-9. PMC: 174037. DOI: 10.1128/iai.64.6.2062-2069.1996. View

Kloprogge F, Hammond R, Kipper K, Gillespie S, Della Pasqua O . Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection. Sci Rep. 2019; 9(1):13228. PMC: 6744479. DOI: 10.1038/s41598-019-49556-5. View

Mukamolova G, Turapov O, Malkin J, Woltmann G, Barer M . Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. Am J Respir Crit Care Med. 2009; 181(2):174-80. PMC: 2809243. DOI: 10.1164/rccm.200905-0661OC. View

Lipworth S, Hammond R, Baron V, Hu Y, Coates A, Gillespie S . Defining dormancy in mycobacterial disease. Tuberculosis (Edinb). 2016; 99:131-142. DOI: 10.1016/j.tube.2016.05.006. View

Muliaditan M, Della Pasqua O . Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis. Br J Clin Pharmacol. 2020; 87(1):140-151. DOI: 10.1111/bcp.14371. View

Prideaux B, Via L, Zimmerman M, Eum S, Sarathy J, OBrien P . The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015; 21(10):1223-7. PMC: 4598290. DOI: 10.1038/nm.3937. View

10.

Billington O, McHugh T, Gillespie S . Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999; 43(8):1866-9. PMC: 89382. DOI: 10.1128/AAC.43.8.1866. View

11.

. Streptomycin in Pulmonary Tuberculosis. Br Med J. 2010; 2(4582):790-1. PMC: 2091854. View

12.

Barisch C, Paschke P, Hagedorn M, Maniak M, Soldati T . Lipid droplet dynamics at early stages of Mycobacterium marinum infection in Dictyostelium. Cell Microbiol. 2015; 17(9):1332-49. DOI: 10.1111/cmi.12437. View

13.

Bowness R, Boeree M, Aarnoutse R, Dawson R, Diacon A, Mangu C . The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. J Antimicrob Chemother. 2014; 70(2):448-55. DOI: 10.1093/jac/dku415. View

14.

Fox W, Ellard G, Mitchison D . Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999; 3(10 Suppl 2):S231-79. View

15.

Garton N, Christensen H, Minnikin D, Adegbola R, Barer M . Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology (Reading). 2002; 148(Pt 10):2951-8. DOI: 10.1099/00221287-148-10-2951. View

16.

Sloan D, Mwandumba H, Garton N, Khoo S, Butterworth A, Allain T . Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clin Infect Dis. 2015; 61(1):1-8. PMC: 4463005. DOI: 10.1093/cid/civ195. View

17.

Fox W, Sutherland I, Daniels M . A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q J Med. 1954; 23(91):347-66. View

18.

Fox W . Whither short-course chemotherapy?. Br J Dis Chest. 1981; 75(4):331-57. DOI: 10.1016/0007-0971(81)90022-x. View

19.

Hammond R, Baron V, Oravcova K, Lipworth S, Gillespie S . Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?. J Antimicrob Chemother. 2015; 70(10):2823-7. DOI: 10.1093/jac/dkv178. View

20.

Keren I, Minami S, Rubin E, Lewis K . Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. mBio. 2011; 2(3):e00100-11. PMC: 3119538. DOI: 10.1128/mBio.00100-11. View